

Magle Chemoswed Holding AB announces the resignation of Julia Kamber Rouhi from the Board of Directors of Magle Chemoswed Holding.

Julia Kamber Rouhi, a deputy member of the Board of Directors of Magle Chemoswed Holding AB (publ) has announced her resignation from the Board of Directors of the company on 16th of August 2022.

Julia Kamber Rouhi has served on the Board for several years and has decided to resign due to personal reasons.

“On behalf of Magle Chemoswed Holding AB and the entire Board, I would like to sincerely thank Julia for her great contributions and commitment. Julia’s knowledge and insights have been extremely valuable to the Board”, said Chairman Hans Henrik Lidgard.

Contacts

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and <https://maglegroup.com/> and www.maglepharmacept.com

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

[Magle Chemoswed Holding AB announces the resignation of Julia Kamber Rouhi from the Board of Directors of Magle Chemoswed Holding.](#)